Jula Inrig - Jan 1, 2022 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
Chief Medical Officer
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Stock symbol
TVTX
Transactions as of
Jan 1, 2022
Transactions value $
$0
Form type
4
Date filed
1/4/2022, 05:09 PM
Next filing
Feb 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Award $0 +20K $0.00 20K Jan 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Stock Option (Right to Buy) Award $0 +80K $0.00 80K Jan 1, 2022 Common Stock 80K $30.60 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.